Medical Device and Healthcare Industry Trends — 2026-06-05

Top 5 Headlines Today

• South Korea's medical device production reaches 12.36 trillion won, grows 8.1% in 2025…achieves sixth consecutive trade surplus — led by dental implants and ultrasound diagnostic equipment

• Samsung Galaxy Watch AI Health Suite unveiled — analyzes sleep and heart rate data with AI to deliver personalized health insights; wearable medical device competition intensifies

• FDA significantly relaxes AI medical device and wearable regulations — streamlines premarket approval requirements for low-risk AI clinical decision support (CDS) and wearables

• GE HealthCare's AI radiotherapy software receives FDA 510(k) clearance — MIM Contour ProtégéAI+ 2.0 clarifies regulatory pathway for medical imaging AI

• Classys Q1 operating margin reaches 42.7%…strengthens global portfolio through Brazilian distributor acquisition — quarterly revenue 8.72 billion won (YoY +13%)

1 sources

regdesk.co

regdesk.co

Key Company Developments

Classys

• What happened: In Q1 2026 earnings report, acquisition of Brazilian distributor MedSystems accelerates profitability and global expansion
• Numbers: Q1 revenue 8.72 billion won (YoY +13%), operating margin 42.7%, operating profit YoY -4.1% (due to one-time accounting adjustments)
• Implications: South Korean medical device companies' strategies to secure overseas distribution networks are materializing. Market entry into emerging markets like Brazil signals strength for strengthening KOSDAQ premium tier listing eligibility.

Samsung Electronics

• What happened: Galaxy Watch platform now equipped with AI-powered health management suite that analyzes users' sleep and heart rate data in real time, delivering personalized health coaching
• Numbers: Galaxy Watch with new AI health module launches June 2026
• Implications: AI integration in wearable medical devices has shifted from optional to essential. Coupled with FDA's relaxed wearable regulations, major tech companies like Samsung are expected to accelerate healthtech investments.

GE HealthCare

• What happened: AI-based radiotherapy automation software 'MIM Contour ProtégéAI+ 2.0' receives FDA 510(k) clearance
• Numbers: FDA 510(k) clearance obtained (June 4, 2026)
• Implications: The FDA regulatory pathway for medical imaging AI is becoming increasingly transparent. Korean medical imaging AI companies like Lunit and Vuno are now better positioned to pursue similar 510(k) pathways for U.S. market entry.

Regulatory Affairs, Policy & Compliance

Discontinuation of MFDS GMP Periodic Inspection Sales Suspension Reprieve

• Details: The MFDS is tightening regulatory standards when in vitro diagnostic device (IVD) GMP validity periods expire. The previous automatic grace period for sales suspension (up to 30 days) is no longer recognized.
• Applies to: All in vitro diagnostic device manufacturers (import, manufacturing, and sales businesses)
• Implementation date: Already in effect (announced March 26, 2026)
• Industry impact: IVD companies must complete GMP validity renewal reviews before expiration. If manufacturing or sales are to continue after expiration, a sales suspension period will occur, making supply chain management increasingly critical.

MFDS Medical Device Approval and Reporting Attachment Guidelines Update

• Details: Updated guidance document for applicants regarding required documents for medical device manufacturing (import) business approval and reporting
• Applies to: Medical device manufacturing, import, and sales business applicants and operators
• Implementation date: Currently posted on the MFDS applicant guidance webpage
• Industry impact: Companies unfamiliar with the latest guidelines may receive supplementary requests during the approval review process. Small startups and smaller firms in particular may face increased consulting costs.

K-Bio Approval and Review Innovation Plan — Biopharmaceutical Review Period Shortened to 240 Days

• Details: The MFDS is pursuing an innovation plan to shorten biopharmaceutical approval and review periods to 240 days, among the world's fastest timelines
• Applies to: Biopharmaceutical (biological drug) license applicants
• Implementation date: Full implementation beginning 2026
• Industry impact: While this policy focuses more on biopharmaceuticals than medical devices, strengthened domestic regulatory competitiveness indirectly benefits medical device companies as well. South Korea's entire medical device and biotech ecosystem gains global competitive advantage.

Digital Health and AI Medicine

• Samsung Galaxy Watch AI Health Coaching: Real-time analysis of sleep, heart rate, and stress through AI delivers personalized health insights; remote health management based on wearables expands

• GE HealthCare MIM Contour ProtégéAI+ 2.0: AI-powered radiotherapy automation software receives FDA 510(k) clearance, clarifying the regulatory pathway for medical imaging AI

• FDA Relaxes Low-Risk AI and Wearable Regulations: Premarket approval requirements streamlined for clinical decision support (CDS) software and non-invasive wearable devices; global barriers to AI medical device market entry fall

Global MedTech Context

• FDA's AI and Wearable Regulation Relaxation — Premarket approval requirements are reduced for low-risk AI clinical decision support and non-invasive wearables, substantially lowering market entry barriers for South Korean medical device and wearable companies entering the U.S. market.

• GE HealthCare's AI Radiotherapy Software Receives FDA 510(k) Clearance — The medical imaging AI regulatory pathway is becoming increasingly clear, and Korean medical imaging AI companies like Lunit and Vuno now have stronger prospects for FDA approval through similar pathways.

• Samsung Galaxy Watch AI Health Platform Expansion — Accelerated healthtech investment by global major companies creates new export opportunities for South Korean medical device component and material suppliers.

Investment, M&A, and Listing Activity

• Classys Acquires Brazilian Distributor MedSystems: Strategic equity acquisition strengthens market entry into Latin America; positive signal for meeting KOSDAQ premium tier listing criteria

Today's Insight

As South Korea's medical device sector maintains its sixth consecutive year of trade surplus in 2025, shifts in the global regulatory environment are accelerating companies' international expansion pace. The FDA's relaxation of AI and wearable regulations opens U.S. market entry opportunities not only for major tech companies like Samsung but also for startups like Lunit and Vuno. Classys's acquisition of a Brazilian distribution network demonstrates that medical device companies hold an advantageous position under the revised KOSDAQ system (premium vs. standard tier), while government support policies such as shortened K-Bio review periods reinforce the industry's competitive strength.

This Week's Checkpoints

• Verify latest MFDS medical device approval guidelines and conduct internal compliance review
• Detailed review of FDA's AI medical device and wearable regulation relaxation guidelines (formal publication expected 2026)
• Monitor Q2 2026 earnings announcements across companies and track overseas sales composition ratios

Reader Action Items

• Regulatory Affairs: Review detailed requirements for MFDS discontinuation of in vitro diagnostic device GMP sales suspension grace periods and recheck validity renewal schedules for your products
• International Business Teams: Assess whether FDA's low-risk AI and wearable regulation relaxation provisions apply to your company's products and reevaluate U.S. market entry timing
• Investors: Prepare for Q2 earnings announcements from Classys, Samsung, and other medical device and wearable companies; update expectations for overseas business performance